Stock Analysis on Net
Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Economic Value Added (EVA)

Microsoft Excel

EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Paying user area


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Economic Profit

Medtronic PLC, economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2026 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The analysis of economic profit indicates a consistent failure to generate returns exceeding the cost of capital throughout the period from 2021 to 2026. Despite the persistence of negative values, there is an observable trend toward the reduction of the economic deficit, suggesting a gradual improvement in the efficiency of value creation.

Net Operating Profit After Taxes (NOPAT)
NOPAT exhibited notable volatility between 2021 and 2024, reaching a peak of 4,888 million in 2022 before declining to a period low of 3,736 million in 2024. A strong recovery is evident in the subsequent years, with NOPAT increasing to 4,980 million in 2025 and reaching 5,540 million by April 2026.
Capital Structure and Cost of Capital
The cost of capital remained relatively stable with a slight downward trajectory, decreasing from 12.28% in 2021 to 11.72% in 2026. Invested capital also showed minimal fluctuation, maintaining a range between 68,670 million and 72,405 million, which indicates a stable capital base over the observed timeframe.
Economic Profit Trajectory
Economic profit remained negative throughout the entire period, signifying that the operating returns were insufficient to cover the capital charge. However, the magnitude of the economic loss narrowed from 4,840 million in 2021 to 2,791 million in 2026. This improvement is primarily attributed to the growth in NOPAT and the marginal reduction in the cost of capital, despite the stable level of invested capital.

Net Operating Profit after Taxes (NOPAT)

Medtronic PLC, NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Net income attributable to Medtronic
Deferred income tax expense (benefit)1
Increase (decrease) in allowances and credit losses2
Increase (decrease) in deferred revenue3
Increase (decrease) in restructuring reserve4
Increase (decrease) in equity equivalents5
Interest expense, net
Interest expense, operating lease liability6
Adjusted interest expense, net
Tax benefit of interest expense, net7
Adjusted interest expense, net, after taxes8
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income9
Investment income, after taxes10
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowances and credit losses.

3 Addition of increase (decrease) in deferred revenue.

4 Addition of increase (decrease) in restructuring reserve.

5 Addition of increase (decrease) in equity equivalents to net income attributable to Medtronic.

6 2026 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

7 2026 Calculation
Tax benefit of interest expense, net = Adjusted interest expense, net × Statutory income tax rate
= × 21.00% =

8 Addition of after taxes interest expense to net income attributable to Medtronic.

9 2026 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

10 Elimination of after taxes investment income.


The analysis of operational profitability and net earnings reveals a cyclical trajectory characterized by a peak in 2022, a subsequent contraction reaching a trough in 2024, and a strong recovery phase through 2026.

Net Operating Profit After Taxes (NOPAT) Trends
NOPAT exhibits significant volatility over the observed period. An initial increase is noted from US$ 4,049 million in 2021 to US$ 4,888 million in 2022, followed by a two-year decline that brings the value down to US$ 3,736 million by 2024. A robust recovery is observed thereafter, with NOPAT ascending to US$ 4,980 million in 2025 and reaching a period high of US$ 5,540 million in 2026. This upward movement in the final two years indicates an expansion in core operational efficiency.
Net Income Performance
Net income attributable to the entity mirrors the general trajectory of NOPAT but demonstrates different magnitudes of change. A sharp increase occurred in 2022, reaching US$ 5,039 million, which was followed by a contraction to US$ 3,758 million in 2023 and a further slight decrease to US$ 3,676 million in 2024. The recovery phase aligns with NOPAT, with net income climbing to US$ 4,801 million by 2026.
Relationship Between Operational Profit and Net Earnings
A comparison between NOPAT and net income reveals that operational profitability generally exceeds the final net income, which is typical given that NOPAT excludes the impact of financing costs. A notable anomaly is observed in 2022, where net income (US$ 5,039 million) surpassed NOPAT (US$ 4,888 million), suggesting the influence of non-operating income or one-time gains. In the subsequent years, the gap widens significantly; by 2026, NOPAT exceeds net income by US$ 739 million, reflecting a strengthening of the core operating engine relative to the final bottom line.

Cash Operating Taxes

Medtronic PLC, cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Income tax provision (benefit)
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense, net
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).


The analysis of tax metrics from April 2021 to April 2026 reveals a period of volatility characterized by a consistent divergence between accounting tax provisions and actual cash tax outflows.

Cash Operating Taxes Trend
Cash operating taxes exhibited a strong upward trajectory between 2021 and 2023, rising from 925 million US$ to a peak of 1,979 million US$. Following this peak, expenditures experienced a moderate decline, eventually stabilizing near 1,428 million US$ in the 2025 and 2026 periods.
Income Tax Provision Volatility
The income tax provision demonstrated more pronounced fluctuations than the cash tax outflows. After an initial increase from 265 million US$ in 2021 to 455 million US$ in 2022, a sharp spike occurred in 2023, reaching 1,580 million US$. This was followed by a downward trend to 936 million US$ by 2025, before rebounding to 1,299 million US$ in 2026.
Comparison of Cash Taxes versus Provisions
A persistent discrepancy is observed where cash operating taxes exceed the income tax provision in every reporting period. This indicates that the actual cash outflows for taxes are consistently higher than the tax expenses recognized for accounting purposes. While the variance was substantial in the early periods—reaching 731 million US$ in 2022—the gap narrowed significantly by 2026, reducing to 129 million US$.

Invested Capital

Medtronic PLC, invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Current debt obligations
Long-term debt
Operating lease liability1
Total reported debt & leases
Shareholders’ equity
Net deferred tax (assets) liabilities2
Allowances and credit losses3
Deferred revenue4
Restructuring reserve5
Equity equivalents6
Accumulated other comprehensive (income) loss, net of tax7
Noncontrolling interests
Adjusted shareholders’ equity
Construction in progress8
Available-for-sale debt securities9
Invested capital

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of deferred revenue.

5 Addition of restructuring reserve.

6 Addition of equity equivalents to shareholders’ equity.

7 Removal of accumulated other comprehensive income.

8 Subtraction of construction in progress.

9 Subtraction of available-for-sale debt securities.


The analysis of invested capital from 2021 to 2026 reveals a period of relative stability, with total invested capital fluctuating within a narrow range between approximately $68.6 billion and $72.4 billion. While the total capital base remained consistent, there were notable shifts in the underlying composition of debt and equity.

Invested Capital Volatility
Invested capital experienced a slight downward trajectory from $72,405 million in 2021 to a trough of $68,670 million in 2024. This was followed by a recovery phase, with values increasing to $70,365 million in 2025 and $71,088 million in 2026. This pattern suggests a disciplined management of the capital base, avoiding aggressive expansion or significant contraction.
Debt and Lease Obligations
Total reported debt and leases exhibited a non-linear trend. Following a decrease from $27,404 million in 2021 to $24,984 million in 2022, debt levels climbed steadily, peaking at $29,626 million in 2025. A marginal reduction to $29,148 million was observed in 2026, indicating a period of increased leverage toward the end of the analyzed timeframe.
Shareholders' Equity Trends
Shareholders' equity showed an inverse relationship with debt levels during several periods. After reaching a peak of $52,551 million in 2022, equity underwent a consistent decline over the next three years, reaching a low of $48,024 million in 2025. A reversal of this trend occurred in 2026, with equity rising back to $49,463 million.

The interaction between the financing components indicates that the increase in debt and leases, particularly between 2023 and 2025, served as a primary offset to the decline in shareholders' equity. This strategic balancing acted to stabilize the total invested capital, ensuring that the operational resource base remained steady despite the shift in the capital structure toward higher leverage.


Cost of Capital

Medtronic PLC, cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2026-04-24).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2025-04-25).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-04-26).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-04-28).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-04-29).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-04-30).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Medtronic PLC, economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Economic profit. See details »

2 Invested capital. See details »

3 2026 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial performance from 2021 through 2026 indicates a sustained period of negative economic value added, although a gradual recovery trajectory is evident in the latter part of the period. The consistent negative economic profit suggests that the return on invested capital has remained below the cost of capital across all observed years.

Economic Profit Analysis
Economic profit remained negative throughout the period, with a peak loss of 4,840 million US$ in 2021. While a temporary improvement occurred in 2022, values declined again in 2023 and 2024. However, a distinct recovery trend emerged starting in 2025, with economic profit improving to negative 3,313 million US$ and further recovering to negative 2,791 million US$ by 2026.
Invested Capital Stability
Invested capital displayed relative stability, fluctuating within a range between 68,670 million US$ and 72,405 million US$. The capital base reached its lowest point in 2024 before beginning a slight ascent toward 71,088 million US$ by 2026. This lack of significant volatility suggests that the changes in economic profit were driven primarily by operational efficiency or shifts in the cost of capital rather than by large-scale changes in the capital employed.
Economic Spread Ratio Trends
The economic spread ratio remained negative throughout the analyzed timeframe, reflecting a continuous destruction of shareholder value. The ratio reached its lowest point in 2021 at -6.68% and experienced another dip in 2024 to -6.50%. A meaningful improvement is observed in the final two years, with the ratio narrowing to -4.71% in 2025 and -3.93% in 2026, indicating a reduction in the gap between the return on invested capital and the weighted average cost of capital.

Economic Profit Margin

Medtronic PLC, economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Economic profit1
 
Net sales
Add: Increase (decrease) in deferred revenue
Adjusted net sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Economic profit. See details »

2 2026 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted net sales
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial trajectory indicates a consistent failure to generate positive economic value over the observed period, although a clear trend of recovery is evident. While economic profit remains negative, the magnitude of the losses has decreased over time, coinciding with a steady expansion in adjusted net sales.

Economic Profit Trends
Economic profit remained in negative territory throughout the six-year period. Significant volatility is observed between 2021 and 2024, with losses fluctuating between 3.5 billion and 4.8 billion USD. However, a sustained recovery began in 2025, with losses narrowing to 3.31 billion USD and further reducing to 2.79 billion USD by 2026.
Adjusted Net Sales Performance
A general upward trend in revenue is observed, with adjusted net sales increasing from 30.18 billion USD in 2021 to 36.42 billion USD in 2026. Aside from a marginal decline in 2023, the growth in sales indicates an expanding operational scale, which serves as the primary driver for the improvement in the economic profit margin.
Economic Profit Margin Analysis
The economic profit margin shows a pattern of overall improvement despite remaining negative. The margin reached its lowest point in 2021 at -16.04%. Following a period of instability, the margin improved significantly in the final two years, reaching -9.88% in 2025 and -7.66% in 2026. This contraction of the negative margin suggests an increase in the efficiency of capital utilization relative to the revenue generated.